The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

Novo Nordisk shares jumped nearly 8% on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill, ...

The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...

Today’s Forbes Daily newsletter features the FDA approval of Wegovy pill, gold prices rise again, AI data centers in space, ...

Monday’s approval gives Novo Nordisk a win against GLP-1 competitor Eli Lilly, which manufactures a weight loss injectable ...

Novo Nordisk A/S won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its ...

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Novo Nordisk A/S's oral Wegovy wins FDA approval, promising strong 2026 growth with market exclusivity and competitive ...

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy (R) pill, the first oral GLP-1 medicine for obesity in the US. (3) Wegovy (R) pill is used ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...